![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study
|
|
|
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
CD Spinner1, A Stoehr2, A Wong3, J de Wet4, J Zeggagh5, L Hocqueloux6, B van Welzen7, M Heinzkill8, S Sahali9, A Torres Cornejo10, H Ramroth11, R Haubrich12, D Thorpe13, CJ Kim14
![1009201](../images/100920/100920-5/1009201.gif)
![1009202](../images/100920/100920-5/1009202.gif)
![1009203](../images/100920/100920-5/1009203.gif)
![1009204](../images/100920/100920-5/1009204.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|